NCT05205707|Completed
Loading search results
Sponsor study identifier
observational
261
1 country
1
Study Start
January 1, 2022
Actual (reported)Primary Completion
January 20, 2022
Actual (reported)Study Completion
January 21, 2022
Actual (reported)COVID-19 cases are rising substantially in Jordan. Since this is a novel virus, there is still much to be investigated surrounding its pathophysiology in order to attempt to find suitable treatments or better decision-making in the prognosis of the disease. This project aims to identify if soluble angiotensin-converting enzyme (ACE2) can be used as a prognostic factor for COVID-19 severity, which will allow clinicians to manage COVID-19 cases more efficiently. ACE2 is of interest since the coronavirus enters host cells through ACE2 receptors. It can slo be hypothesized that the irus may also bind to soluble ACE2, but without mediating its effects. It si, therefore, expected that those with higher levels of ACE2 would more likely have milder disease. This can potentially help improve survival rate, allowing clinicians to identify the higher-risk patients and monitoring them more closely.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 21, 2022
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 1, 2022
Actual (reported)January 20, 2022
Actual (reported)January 21, 2022
Actual (reported)January 22, 2022
Actual (reported)January 25, 2022
Actual (reported)ACE2 level
Serum level of ACE2 in control and COVID 19 patients will be measured
3 months
Blood sample from admitted patients will be drawn
Blood sample from control group will be drawn
Circulating ACE2 level will be measured
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
All adult COVID 19 patients admitted to Jordan University Hospital during 3 months.
The University of Jordan
Amman, 11972, Jordan
261 participants (actual enrollment reported by the registry).
First Submitted
January 22, 2022
First Posted
January 25, 2022
Study Start
January 1, 2022
Actual (reported)The Effect of Omega -3 Supplements on the Serum Levels of ACE/ACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People
Contact the study team to confirm eligibility.
Primary Completion
January 20, 2022
Actual (reported)Study Completion
January 21, 2022
Actual (reported)Last Updated
February 8, 2022
Record last verified: 2022-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: